Gene expression microarray analysis reveals @entity9086 to be a potential serum marker for malignant character in XXXX @entity11 .

@entity1 @entity571 @entity0 @entity5 @entity11 @entity9086 @entity14 @entity1575 @entity463 @entity309
We have identified a potential serum marker for @entity463 ( @entity463 ) using microarray analysis from samples of @entity463 . We compared the gene expression profile of 19 @entity11 to pooled normal brain by competitive hybridization of RNA from each @entity5 sample to a pooled sample of RNA isolated from normal brain tissue using the Incyte 10,000 gene expression array. The most differentially expressed gene in this analysis encodes a secreted glycoprotein and is referred to as @entity9086 . @entity9086 mRNA was detected in the @entity463 samples with a range of 3- to 62-fold elevation over normal brain. It has been reported previously that this protein is expressed in pathologic conditions of extracellular matrix degradation and angiogenesis, such as @entity309 , severe @entity571 , @entity1575 , primary @entity14 , and metastatic @entity0 . These data suggest @entity9086 may be involved in extracellular matrix degradation and/or angiogenesis. Western blot analysis of @entity11 samples for @entity9086 protein levels revealed substantial elevation in approximately 65% of GBMs and undetectable levels in lower-grade @entity11 (grade II and III) or normal brain tissue. We performed ELISA analysis on serum samples of @entity11 @entity1 to determine whether this protein would correlate with the presence of @entity5 and @entity5 grade or burden. @entity9086 serum levels were substantially elevated in many of the @entity463 @entity1 . Statistical analysis of these data indicates that in @entity1 with @entity11 , serum @entity9086 levels correlate with @entity5 grade and potentially @entity5 burden in @entity463 .
